The Solid Tumor Market in Europe is estimated to hike at a robust CAGR during the forecast period.
Solid tumors are formed due to the aggregation of abnormal tissues that do not comprise of any cyst or liquid areas within.
They are mainly of two types- malignant and benign. Most of the solid tumors are treated via radiotherapy, chemotherapy or surgery. Various chemotherapeutic drugs are available in the market along with a ripe pipeline of drugs that will soon be commercialized.
Some of the major driving factors for the growth of this market include rise in the number of cancer cases, increasing incidences of several cases of solid tumors. Due to rise in the number of cases, there has been an increasing demand for highly effective chemotherapeutic agents which in turn drives the market. Many companies are investing in various R&D projects related to therapeutics which fuels the market growth.
However, increasing generic products, high cost of therapy, increasing cost of R&D and various drugs going off patent, are turning out to be restraints for the market.
This research report has been segmented and sub-segmented into the following categories:
By Disease
By Drugs
By Country
Regionally, Europe is the second largest market due to a large geriatric population which contributes heavily to the growth of the solid tumor market.
Companies dominating the European Solid Tumor Market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Disease
5.1.1 Introduction
5.1.2 Breast cancer
5.1.3 Lung cancer
5.1.4 Colorectal cancer
5.1.5 Prostate cancer
5.1.6 Cervical cancer
5.1.7 Others
5.1.8 Y-o-Y Growth Analysis, By disease
5.1.9 Market Attractiveness Analysis, By disease
5.1.10 Market Share Analysis, By disease
5.2 Drugs
5.2.1 Introduction
5.2.2 Carboplatin
5.2.3 Cisplatin
5.2.4 Gemcitabine
5.2.5 Paclitaxel
5.2.6 Doxorubicin
5.2.7 Bevacizumab
5.2.8 Erlotinib
5.2.9 Sunitinib
5.2.10 Everolimus
5.2.11 Docetaxel
5.2.12 Abiraterone
5.2.13 Abiraterone acetate
5.2.14 Cabazitaxel
5.2.15 Y-o-Y Growth Analysis, By Drugs
5.2.16 Market Attractiveness Analysis, By drugs
5.2.17 Market Share Analysis, By drugs
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By disease
6.1.3.3 By drugs
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By disease
6.1.4.3 By drugs
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By disease
6.1.5.3 By drugs
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Boehringer Ingelheim GmbH
8.3 Baxter International
8.4 Bristol-Myers Squibb Company
8.5 F. Hoffmann-La Roche Ltd.
8.6 Eli Lilly and Company
8.7 Johnson & Johnson
8.8 GlaxoSmithKline plc
8.9 Kyowa Hakko Kirin Co., Ltd.
8.10 Sanofi
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
